| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
47,830,000 |
| Market
Cap: |
78.44(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.13 - $3.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a main role. Co. is developing uproleselan, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia, a hematologic cancer, and potentially other hematologic cancers. Co. is also developing a drug candidate, GMI-1359, that simultaneously targets both E-selectin and a chemokine receptor known as CXCR4. Co. has designed an antagonist of E-selectin, GMI-1687, that could be suitable for subcutaneous administration.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
108,903 |
2,581,565 |
| Total Buy Value |
$0 |
$0 |
$158,251 |
$4,837,462 |
| Total People Bought |
0 |
0 |
3 |
9 |
| Total Buy Transactions |
0 |
0 |
4 |
21 |
| Total Shares Sold |
0 |
0 |
3,700 |
4,053,849 |
| Total Sell Value |
$0 |
$0 |
$7,215 |
$12,677,616 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Junius Daniel M |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$15,627 |
D/D |
5,209 |
98,459 |
|
- |
|
| Goldberg Mark Alan |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$13,752 |
D/D |
4,584 |
24,828 |
|
- |
|
| King Rachel K. |
|
– • – |
2024-03-29 |
4 |
A |
$3.00 |
$10,002 |
D/D |
3,334 |
515,194 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$13,752 |
D/D |
5,827 |
20,244 |
|
- |
|
| Andrews Patricia S |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$12,251 |
D/D |
5,191 |
58,608 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2023-12-29 |
4 |
A |
$2.36 |
$10,002 |
D/D |
4,238 |
511,860 |
|
- |
|
| Goldberg Mark Alan |
Director |
– • – |
2023-09-30 |
4 |
A |
$1.50 |
$13,751 |
D/D |
9,167 |
14,417 |
|
- |
|
| King Rachel K. |
Director |
– • – |
2023-09-30 |
4 |
A |
$1.50 |
$10,001 |
D/D |
6,667 |
507,622 |
|
- |
|
| Andrews Patricia S |
Director |
– • – |
2023-09-30 |
4 |
A |
$1.50 |
$12,251 |
D/D |
8,167 |
53,417 |
|
- |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2023-09-22 |
4 |
B |
$1.38 |
$41,956 |
D/D |
30,403 |
375,403 |
2.74 |
108% |
|
| Rock Edwin |
Chief Medical Officer |
• – – |
2023-09-21 |
4 |
B |
$1.38 |
$48,300 |
D/D |
35,000 |
345,000 |
2.74 |
117% |
|
| Koenig Scott |
Director |
– • – |
2023-06-01 |
4 |
OE |
$0.60 |
$12,600 |
D/D |
21,000 |
36,750 |
|
- |
|
| Hahn Brian M. |
SVP Finance, CFO |
• – – |
2023-05-17 |
4 |
S |
$1.95 |
$7,215 |
D/D |
(3,700) |
53,143 |
|
30% |
|
| Junius Daniel M |
Director |
– • – |
2023-05-10 |
4 |
B |
$1.56 |
$46,800 |
D/D |
30,000 |
93,250 |
2.39 |
-18% |
|
| Johnson Bruce S |
SVP & Chief Commercial Officer |
• – – |
2023-05-08 |
4 |
B |
$1.57 |
$21,195 |
D/D |
13,500 |
138,980 |
2.74 |
-5% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-24 |
4 |
B |
$1.70 |
$170,000 |
D/D |
100,000 |
8,589,064 |
2.45 |
-2% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-23 |
4 |
B |
$1.75 |
$350,760 |
D/D |
200,000 |
8,489,064 |
2.45 |
-1% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-22 |
4 |
B |
$1.79 |
$268,995 |
D/D |
150,000 |
8,289,064 |
2.45 |
-3% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-21 |
4 |
B |
$1.85 |
$92,500 |
D/D |
50,000 |
8,139,064 |
2.45 |
-9% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-17 |
4 |
B |
$1.71 |
$341,000 |
D/D |
200,000 |
8,089,064 |
2.45 |
-9% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-16 |
4 |
B |
$1.68 |
$531,129 |
D/D |
315,266 |
7,889,064 |
2.45 |
-2% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-15 |
4 |
B |
$2.16 |
$2,155,800 |
D/D |
1,000,000 |
7,573,798 |
2.45 |
19% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,562,347 |
|
-45% |
|
| Invus Public Equities Advisors, Llc |
10% Owner |
– – • |
2023-02-09 |
4 |
B |
$3.24 |
$37,123 |
D/D |
11,451 |
6,573,798 |
2.37 |
-45% |
|
| Koenig Scott |
Director |
– • – |
2023-01-27 |
4 |
OE |
$2.55 |
$26,775 |
D/D |
10,500 |
15,750 |
|
- |
|
116 Records found
|
|
Page 1 of 5 |
|
|
0.07 (4.09%) 
